Financial conflicts of interest in Japanese obstetrics and gynaecology clinical practice guidelines

Anju Murayama; Keishi Miyazawa; Sae Kamamoto; Haruki Shigeta; Hinari Kugo; Kenichi Higuchi; Yuki Senoo

doi:10.1002/ctd2.273

Clinical and Translational Discovery ›› 2024, Vol. 4 ›› Issue (1) :e273 DOI: 10.1002/ctd2.273

COMMENTARY

Financial conflicts of interest in Japanese obstetrics and gynaecology clinical practice guidelines

Author information +

History +

PDF

Abstract

This commentary analysis evaluated the size and prevalence of financial conflicts of interest among authors of Japanese obstetrics and gynaecology clinical practice guidelines. Our analysis found that 66% of all authors received personal payments totalling US$1.2 million during the guideline development period. Furthermore, the guideline chairpersons received much larger payments than those to other authors.

Keywords

clinical practice guidelines / conflicts of interest / evidence-based medicine / gynaecology / obstetrics

Cite this article

Download citation ▾

Anju Murayama, Keishi Miyazawa, Sae Kamamoto, Haruki Shigeta, Hinari Kugo, Kenichi Higuchi, Yuki Senoo. Financial conflicts of interest in Japanese obstetrics and gynaecology clinical practice guidelines. Clinical and Translational Discovery, 2024, 4(1): e273 DOI:10.1002/ctd2.273

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Institute of Medicine. Clinical Practice Guidelines We Can Trust. The National Academies Press; 2011.

[2]	WrightMR, FryeL, Vo SolisL, et al. Evaluating financial conflicts of interest among contributors to clinical practice guidelines of the American College of Obstetricians and Gynecologists. J Am Osteopath Assoc. 2020;120(7):462-470.

[3]	SaitoH, OzakiA, KobayashiY, Sawano T, TanimotoT. Pharmaceutical company payments to executive board members of professional medical associations in Japan. JAMA Intern Med. 2019;179(4):578-580.

[4]	Medical Governance Research Institute. Yen for docs. [Online database]. 2023 Accessed December 2–9, 2023. Available from:

[5]	MurayamaA, Kamamoto S, MurataN, et al. Evaluation of financial conflicts of interest and quality of evidence in Japanese gastroenterology clinical practice guidelines. J Gastroenterol Hepatol. 2023;38(4):565-573.

[6]	MurayamaA, YamadaK, YoshidaM, et al. Evaluation of conflicts of interest among participants of the Japanese Nephrology Clinical Practice Guideline. Clin J Am Soc Nephrol. 2022;17(6):819-826.

[7]

MamadaH, Murayama A, KamamotoS, et al. Evaluation of financial and nonfinancial conflicts of interest and quality of evidence underlying Psoriatic Arthritis Clinical Practice Guidelines: analysis of personal payments from pharmaceutical companies and authors' self-citation rate in Japan and the United States. Arthritis Care Res. 2023;75(6):1278-1286.

[8]	MurayamaA. Financial conflicts of interest among the authors of the clinical practice guidelines for rheumatoid arthritis in Japan. Cureus. 2023;15(10):e46650.

[9]	MamadaH, Murayama A, OzakiA, et al. Observational study of financial and non-financial conflicts of interest among the Japanese government advisory board members concerning coronavirus disease 2019. Medicine. 2023;102(4):e32776.

[10]	KidaF, Murayama A, SaitoH, OzakiA, Shimada Y, TanimotoT. Pharmaceutical company payments to authors of the Japanese Clinical Practice Guidelines for Hepatitis C treatment. Liver Int. 2021;41(3):464-469.

[11]	MurayamaA, SaitoH, TanimotoT, Ozaki A. Financial conflicts of interest between pharmaceutical companies and executive board members of internal medicine subspecialty societies in Japan between 2016 and 2020. J Eval Clin Pract. 2023;29(6):883-886.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.